OTUD6B and triple-negative breast carcinoma: Furthermore, OTUD6B facilitated tumor progression in many cancers, including lung adenocarcinoma, laryngeal squamous cell carcinoma, triple-negative breast cancer, and cholangiocarcinoma [10, 21–23].